News
MRNA
33.47
-5.81%
-2.07
Benjamin Graham Detailed Fundamental Analysis - MRNA
NASDAQ · 1h ago
Vaccine Stocks Rise as Chinese Scientists Discover a New Coronavirus
NASDAQ · 2h ago
Stocks to Watch Monday: Domino's, Berkshire Hathaway; Alibaba
The Wall Street Journal · 5h ago
NIH Funding Cuts To Spook Healthcare Stocks? RFK Jr's Confirmation At HHS Sparks Concerns Over Research Dollars, 'Causing Uncertainty,' Says Analyst
Benzinga · 5h ago
Weekly Report: what happened at MRNA last week (0217-0221)?
Weekly Report · 7h ago
Notable healthcare headlines for the week: UnitedHealth, Moderna, Sanofi in focus
Seeking Alpha · 1d ago
Moderna’s 2024 Struggles: Navigating Commercial Challenges and Market Competition in the Vaccine Industry
TipRanks · 2d ago
Moderna Inc. Stock Climbs 5.3%, Outperforms Competitors
Dow Jones · 2d ago
3 Biotech/Healthcare Names Under $10 I Am Buying Now
Seeking Alpha · 2d ago
Noteworthy Friday Option Activity: ABR, INOD, MRNA
NASDAQ · 2d ago
Moderna, Novavax rise as new bat coronavirus identified in China
Seeking Alpha · 2d ago
Moderna call volume above normal and directionally bullish
TipRanks · 2d ago
New coronavirus with ‘pandemic potential’ found in China, Daily Mail says
TipRanks · 2d ago
'New Coronavirus With Pandemic Potential Discovered In China' - DailyMail
Benzinga · 2d ago
Big Pharma: Seeking Alpha Analysts vs. Wall Street
Seeking Alpha · 2d ago
Deregulation exposure was the most valuable characteristic of a stock owned by hedge funds – GS
Seeking Alpha · 2d ago
Stocks Finish Sharply Lower on Economic Concerns
Barchart · 3d ago
First meeting of CDC vaccine advisory panel under RFK Jr. postponed
Seeking Alpha · 3d ago
Moderna Inc. Stock Sheds 6.0%, Underperforms Competitors
Dow Jones · 3d ago
Eli Lilly (LLY) Stockpiles Weight Loss Pill Ahead of Regulatory Approval
TipRanks · 3d ago
More
Webull provides a variety of real-time MRNA stock news. You can receive the latest news about Moderna through multiple platforms. This information may help you make smarter investment decisions.
About MRNA
More
Moderna, Inc. is a biotechnology company. The Company is advancing a new class of medicines made of messenger ribonucleic acid (mRNA). It is developing therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases and autoimmune diseases, independently and with its strategic collaborators. mRNA medicines are designed to direct the body’s cells to produce intracellular, membrane or secreted proteins that have a therapeutic or preventive benefit with the potential to address a spectrum of diseases. Its diverse development pipeline consists of 45 therapeutic and vaccine programs, nine of which are in late-stage development. Its products include COVID-19 vaccines (mRNA-1273/Spikevax, next-generation mRNA-1283), RSV vaccine (mRNA-1345), Seasonal influenza vaccines (mRNA-1010, mRNA-1011, mRNA-1012, mRNA-1020 and mRNA-1030), Combination vaccines (mRNA-1083, mRNA-1230, mRNA-1045 and mRNA-1365), CMV vaccine (mRNA-1647), EBV vaccine (mRNA-1189 and mRNA-1195) and others.